TGen, Flagship Partner to Hasten Drug Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – TGen Drug Development and Flagship Biosciences today announced a partnership to use their technologies to hasten new drug development.

The deal combines TGen's molecular analysis tools with Flagship's expertise in high-throughput immunohistochemistry to support preclinical drug development and human clinical trials.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.